Phacilitate Leaders Forum

Speakers

Loading
David Hodl

David Hodl

Vice President Business Development for Cell Therapy, Invetech

David is the Vice President of Business Development, Cell Therapy for Invetech. David has over 21 years of experience in product commercialization and business development roles. Prior to joining Invetech David led the Cell Processing business unit of SynGen, commercializing equipment and single-use consumables for manufacturing cell-based therapies. He also spent eight years in a business development role with Becton Dickinson’s Corporate Innovation Center, focusing on commercialization of cell-based and next-generation sequencing technologies. David earned an MBA from North Carolina State University and a BA in biology from Linfield College.

Sessions
Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd